Back

Dual inhibition of SGLT 1 and 2 alleviates intracellular sodium overload in uraemic cardiomyopathy

1 September 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Novel insights into cardiometabolism Metabolism ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Megan Young

Queen Mary University of London, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
ATM: a protein involved in glucose and lipid metabolism in the heart
Mrs M. Carotenuto (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Monocytic mitochondrial dysfunction and impaired monocytic bioenergetic profile in patients with heart failure symptoms in post-COVID syndrome
Doctor D. Semo (Munster, DE)
Abstract Slides Video
Presentation thumbnail
ND15, subunit of the electron transport chain protein-complex I, age-dependently worsens cardiac performance in Drosophila melanogaster
Mr F. Gaub (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Moderate intensity exercise training ameliorates the heart failure with preserved ejection fraction phenotype in a preclinical model by improving cardiometabolic fitness
Doctor A. Chitroceanu (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Higher myocardial mitochondrial ketone body oxidation capacity in human heart failure
Mr J. Schmidt (Duesseldorf, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Novel insights into cardiometabolism

The Event

Event poster

ESC Congress 2024

1 September 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Effect of SGLT2i on myocardial remodeling due to cardiorenal syndrome in rat model of heart failure
thumbnail
Congress Presentation
Effects of empagliflozin on cardio-renal interaction in heart failure with reduced ejection fraction: results from in-vivo experiments and the CINNAMON-study
thumbnail
Congress Presentation
Sodium-glucose cotransporter 2 inhibitors alter cardiac glucose transporter expression in patients with heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources